Class of 2016 Abstract / Objectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma.
Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least one dose of ipilimumab.
Results: The primary finding of this study is that 38% of patients used at least 20 mg of prednisone daily or more while on Ipilimumab therapy. Only 33% of patients had endocrine lab values reported.
Conclusions: There was not enough data collected to adequately show that Ipilimumab affects the endocrine system. There was also insufficient reporting of appropriate serum levels. More research on the importance of reporting lab values while on ipilimumab therapy needs to be conducted.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/613945 |
| Date | January 2016 |
| Creators | Qyra, Ollga, McBride, Ali |
| Contributors | McBride, Ali, College of Pharmacy, The University of Arizona |
| Publisher | The University of Arizona. |
| Source Sets | University of Arizona |
| Language | en_US |
| Detected Language | English |
| Type | text, Electronic Report |
| Rights | Copyright © is held by the author. |
Page generated in 0.0022 seconds